Edulis Therapeutics
Private Company
Total funding raised: $50M
Overview
Edulis Therapeutics is an early-stage biotechnology company pioneering a novel endoscopic drug delivery platform for gastrointestinal medicine. Its lead program targets inflammatory bowel disease (IBD), with a pipeline exploring applications in microbiome modulation and weight loss. The company's value proposition centers on improving patient quality of life through a long-acting, localized delivery system that aims to enhance drug bioavailability, reduce systemic side effects, and lower overall treatment costs. Backed by grant funding and competition accolades, Edulis is developing both the therapeutic implants and the associated endoscopic insertion tool as an integrated platform.
Technology Platform
Endoscopic drug delivery system using a bioresorbable polymer matrix implant, thinner than a grain of rice, for localized, sustained release of small molecule drugs in the GI tract for up to 12 months.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Edulis competes with large pharma companies developing new systemic drugs for IBD and obesity, as well as other drug delivery startups. Its unique differentiator is the endoscopic, long-acting localized delivery approach for the GI tract, a niche not yet addressed by approved therapies. Competition will intensify from other extended-release technologies and potentially from improved oral formulations.